These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38155243)

  • 1. Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine.
    Lv K; Kong F; Yu M; Zhou Y; Li F
    Ann Hematol; 2024 Mar; 103(3):1017-1019. PubMed ID: 38155243
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficacy and safety of Polatuzumab Vedotin in combination with rituximab plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma: a single center analysis].
    Kong FC; Yu M; Zhou YL; Wang SX; Li F
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):66-69. PubMed ID: 35231996
    [No Abstract]   [Full Text] [Related]  

  • 3. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.
    Dal MS; Ulu BU; Uzay A; Akay OM; Beşışık S; Yenerel MN; Çelik S; Kaynar L; Yücel OK; Deveci B; Sönmez M; Mehtap Ö; Beköz HS; Sunu C; Salim O; Ulaş T; Kartı S; Altuntaş F; Ferhanoğlu B; Tuğlular TF
    Ann Hematol; 2023 Jan; 102(1):133-140. PubMed ID: 36401621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
    Amaya ML; Jimeno A; Kamdar M
    Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.
    Saburi M; Sakata M; Kodama Y; Uraisami K; Takata H; Miyazaki Y; Wada J; Urabe S; Ohtsuka E
    J Clin Exp Hematop; 2023 Sep; 63(3):201-204. PubMed ID: 37518271
    [No Abstract]   [Full Text] [Related]  

  • 6. Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma.
    Takakuwa T; Okayama Y; Nakamae H; Kuno M; Makuuchi Y; Harada N; Okamura H; Nishimoto M; Nakashima Y; Koh H; Hino M
    Ann Hematol; 2022 Jul; 101(7):1609-1610. PubMed ID: 35218398
    [No Abstract]   [Full Text] [Related]  

  • 7. Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
    Shinmura K; Okubo S; Kadota S; Nakayama H; Sakurai A; Kurosawa S; Ito C; Aisa Y; Nakazato T
    Ann Hematol; 2023 Jan; 102(1):223-225. PubMed ID: 36394579
    [No Abstract]   [Full Text] [Related]  

  • 8. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ
    J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
    Flowers CR; Matasar MJ; Herrera AF; Hertzberg M; Assouline S; Demeter J; McMillan A; Mehta A; Opat S; Trnňný M; Musick L; Hirata J; Yang A; Sehn LH
    Haematologica; 2024 Apr; 109(4):1194-1205. PubMed ID: 37767550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.
    Tarantelli C; Bertoni F
    Br J Haematol; 2022 Oct; 199(2):169-170. PubMed ID: 35917107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
    Betts KA; Thuresson PO; Felizzi F; Du EX; Dieye I; Li J; Schulz M; Masaquel AS
    J Comp Eff Res; 2020 Oct; 9(14):1003-1015. PubMed ID: 33028076
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
    Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
    Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
    Choi Y; Diefenbach CS
    Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
    Walji M; Assouline S
    Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
    Wang YW; Tsai XC; Hou HA; Tien FM; Liu JH; Chou WC; Ko BS; Chen YW; Lin CC; Cheng CL; Lo MY; Lin YC; Lu LC; Wu SJ; Kuo SH; Hong RL; Huang TC; Yao M
    Ann Hematol; 2022 Feb; 101(2):349-358. PubMed ID: 34766217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    Vodicka P; Benesova K; Janikova A; Prochazka V; Belada D; Mocikova H; Steinerova K; Duras J; Karban J; Hanackova V; Sykorova A; Obr A; Trneny M
    Eur J Haematol; 2022 Aug; 109(2):162-165. PubMed ID: 35502609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
    Dimou M; Papageorgiou SG; Stavroyianni N; Katodritou E; Tsirogianni M; Kalpadakis C; Banti A; Arapaki M; Iliakis T; Bouzani M; Verrou E; Spanoudakis E; Giannouli S; Marinakis T; Mandala E; Mparmparousi D; Sachanas S; Dalekou-Tsolakou M; Hatzimichael E; Vadikolia C; Violaki V; Poziopoulos C; Tsirkinidis P; Chatzileontiadou S; Vervessou E; Ximeri M; Sioni A; Konstantinidou P; Kyrtsonis MC; Siakantaris MP; Angelopoulou MK; Pappa V; Konstantopoulos K; Panayiotidis P; Vassilakopoulos TP
    Hematol Oncol; 2021 Aug; 39(3):336-348. PubMed ID: 33583077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
    Malecek MK; Watkins MP; Bartlett NL
    Expert Opin Biol Ther; 2021 Jul; 21(7):831-839. PubMed ID: 32500753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
    Morita Y; Yagi Y; Kanemasa Y; Sasaki Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Ohashi K; Shimoyama T
    Rinsho Ketsueki; 2023; 64(7):586-595. PubMed ID: 37544717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Abrisqueta P; González-Barca E; Panizo C; Pérez JMA; Miall F; Bastos-Oreiro M; Triguero A; Banerjee L; McMillan A; Seymour E; Hirata J; de Guzman J; Sharma S; Jin HY; Musick L; Diefenbach C
    Lancet Haematol; 2024 Feb; 11(2):e136-e146. PubMed ID: 38190832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.